GSK Financial Analysis
GSK Key Indicators
GSK Income Statement
GSK Balance Sheet
GSK Cash Flow
Quarterly
| FY2024Q4 | FY2024Q3 | FY2024Q2 | FY2024Q1 | FY2023Q4 | FY2023Q3 | FY2023Q2 | FY2023Q1 | FY2022Q4 | FY2022Q3 | FY2022Q2 | FY2022Q1 | FY2021Q4 | FY2021Q3 | FY2021Q2 | FY2021Q1 | FY2020Q4 | FY2020Q3 | FY2020Q2 | FY2020Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 10.40B 4.04% | 10.42B 1.05% | 9.95B 10.73% | 9.34B 10.61% | 10.00B 15.61% | 10.31B 11.94% | 8.98B 3.11% | 8.44B -35.64% | 8.65B -9.34% | 9.21B 0.83% | 8.71B 6.83% | 13.12B 28.32% | 9.54B -17.36% | 9.13B -18.13% | 8.15B -13.78% | 10.22B -12.11% | 11.54B 0.75% | 11.16B -3.56% | 9.46B -5.78% | 11.63B |
Revenue from Goods & Services | 10.40B 4.04% | 10.42B 1.05% | 9.95B 10.73% | 9.34B 10.61% | 10.00B 15.61% | 10.31B 11.94% | 8.98B 3.11% | 8.44B -35.64% | 8.65B -9.34% | 9.21B 0.83% | 8.71B 6.83% | 13.12B 28.32% | 9.54B -17.36% | 9.13B -18.13% | 8.15B -13.78% | 10.22B -12.11% | 11.54B 0.75% | 11.16B -3.56% | 9.46B -5.78% | 11.63B |
Cost of Goods Sold | 3.23B 11.57% | 3.02B 6.80% | 2.59B 9.61% | 2.43B 5.08% | 2.90B 13.50% | 2.83B 0.76% | 2.37B -11.83% | 2.31B -52.72% | 2.55B -31.42% | 2.81B 3.79% | 2.69B 14.24% | 4.89B 47.14% | 3.72B -4.87% | 2.70B -22.90% | 2.35B -21.98% | 3.32B -6.63% | 3.91B 0.93% | 3.51B -4.39% | 3.01B -3.57% | 3.56B |
Gross Profit | 7.17B 0.97% | 7.40B -1.12% | 7.35B 11.13% | 6.91B 12.70% | 7.10B 16.50% | 7.48B 16.84% | 6.61B 9.77% | 6.13B -25.49% | 6.09B 4.79% | 6.40B -0.42% | 6.03B 3.83% | 8.23B 19.25% | 5.81B -23.77% | 6.43B -15.95% | 5.80B -9.94% | 6.90B -14.53% | 7.63B 0.66% | 7.65B -3.17% | 6.44B -6.78% | 8.07B |
Selling General & Administrative Expenses | 5.81B 6.81% | 4.57B -0.73% | 4.61B 4.39% | 4.25B 5.91% | 5.44B 16.89% | 4.60B 18.78% | 4.41B 11.92% | 4.01B -22.42% | 4.66B 3.83% | 3.87B 1.73% | 3.94B 1.65% | 5.17B 9.86% | 4.48B -20.03% | 3.81B -16.74% | 3.88B -15.90% | 4.71B -5.35% | 5.61B 1.40% | 4.57B -6.03% | 4.61B 2.81% | 4.98B |
Research & Development Expense | 2.33B 5.35% | 1.86B 2.68% | 1.78B 8.48% | 1.72B 16.13% | 2.21B 24.14% | 1.81B 18.52% | 1.65B 13.33% | 1.48B -4.10% | 1.78B 3.02% | 1.53B -0.45% | 1.45B -6.00% | 1.55B 4.29% | 1.73B 1.11% | 1.53B 13.22% | 1.54B 6.35% | 1.48B 6.80% | 1.71B 14.32% | 1.35B -5.66% | 1.45B 8.66% | 1.39B |
Other Operating Expense - Net | 215.24M -48.40% | -218.44M -44.67% | -181.65M -35.76% | -191.50M -12.40% | 417.09M -272.74% | -394.80M 31.62% | -282.79M 41.48% | -218.61M 17.27% | -241.45M 30.78% | -299.96M 90.91% | -199.88M 85.87% | -186.41M 48.67% | -184.62M 53.65% | -157.13M 43.25% | -107.54M 15.60% | -125.39M 46.27% | -120.16M 13.86% | -109.69M -24.59% | -93.02M -7.20% | -85.72M |
Operating Profit | 1.14B -8.06% | 3.05B -6.93% | 2.93B 17.77% | 2.85B 22.02% | 1.24B -26.19% | 3.28B 15.75% | 2.49B 8.85% | 2.34B -27.92% | 1.68B 10.81% | 2.83B 1.80% | 2.28B 12.34% | 3.24B 39.97% | 1.51B -29.23% | 2.78B -12.77% | 2.03B 5.56% | 2.31B -27.25% | 2.14B -0.59% | 3.19B 0.23% | 1.92B -23.82% | 3.18B |
Financing Income- Net | -178.08M -25.67% | -161.23M -19.36% | -189.22M -0.51% | -169.94M -19.58% | -239.58M -16.23% | -199.93M -4.52% | -190.19M -17.32% | -211.32M -21.99% | -285.99M 13.49% | -209.39M -20.46% | -230.05M -10.96% | -270.90M 2.93% | -252.00M -18.44% | -263.25M 3.03% | -258.37M -8.64% | -263.19M 9.41% | -308.98M 23.12% | -255.51M -2.69% | -282.79M 1.87% | -240.54M |
Interest Expense | 178.08M -25.67% | 161.23M -19.36% | 189.22M -0.51% | 169.94M -19.58% | 239.58M -16.23% | 199.93M -4.52% | 190.19M -17.32% | 211.32M -21.99% | 285.99M 13.49% | 209.39M -20.46% | 230.05M -10.96% | 270.90M 2.93% | 252.00M -18.44% | 263.25M 4.62% | 258.37M -8.64% | 263.19M 9.41% | 308.98M 23.12% | 251.64M -4.16% | 282.79M 1.87% | 240.54M |
Non-Interest Financial Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 -100.00% | 0.00 | 0.00 | 0.00 | -3.87M | 0.00 | 0.00 |
Other Non-Operating Income | -19.22M | 0.00 -100.00% | 0.00 | 0.00 | 0.00 -100.00% | -2.53M | 0.00 | 0.00 | 14.07M 247.91% | 0.00 | 0.00 | 0.00 -100.00% | 4.04M 206.17% | 0.00 -100.00% | 0.00 -100.00% | 1.38M 7.70% | 1.32M -151.30% | 1.29M -85.04% | 1.24M -51.75% | 1.28M |
Income before Taxes | 721.30M 52.91% | 84.51M -96.27% | 1.89B -24.17% | 1.72B -25.83% | 471.71M -75.22% | 2.27B 90.19% | 2.49B 120.47% | 2.32B -33.48% | 1.90B 363.11% | 1.19B -27.29% | 1.13B -23.31% | 3.49B 68.41% | 411.02M -62.36% | 1.64B -23.50% | 1.47B -54.74% | 2.07B -11.41% | 1.09B -50.29% | 2.14B -10.14% | 3.25B 99.56% | 2.34B |
Income Taxes | 79.43M -436.79% | -1.30M -100.40% | 240.94M -20.43% | 347.49M 3.67% | -23.59M -2112.26% | 325.21M 18.65% | 302.81M 60.59% | 335.20M -42.01% | 1.17M -100.74% | 274.08M -19.16% | 188.56M -167.17% | 578.02M 62.59% | -157.67M 563.38% | 339.06M 9.02% | -280.72M -212.60% | 355.51M 78.11% | -23.77M -109.52% | 311.00M 7.36% | 249.31M -9.36% | 199.60M |
Net Income after Tax | 641.87M 29.59% | 85.81M -95.58% | 1.65B -24.69% | 1.37B -30.81% | 495.30M -73.96% | 1.94B 111.56% | 2.19B 132.47% | 1.98B -31.79% | 1.90B 234.51% | 917.54M -29.41% | 940.31M -46.35% | 2.91B 69.62% | 568.69M -49.03% | 1.30B -29.02% | 1.75B -41.63% | 1.71B -19.78% | 1.12B -42.70% | 1.83B -12.57% | 3.00B 121.67% | 2.14B |
Minority Interest | 111.46M 87.07% | 159.93M 80.55% | 165.25M 9.15% | 44.39M -74.08% | 59.58M -59.33% | 88.58M 98.16% | 151.40M -12.09% | 171.24M -65.02% | 146.51M -39.93% | 44.70M -83.78% | 172.22M -13.77% | 489.51M 89.97% | 243.92M 14.03% | 275.66M 14.85% | 199.72M -9.03% | 257.67M 76.66% | 213.91M -23.76% | 240.03M 18.73% | 219.54M 98.63% | 145.86M |
Income Available to Common Shares | 530.41M 22.08% | -75.41M -104.07% | 1.48B -27.18% | 1.33B -26.69% | 434.47M -81.48% | 1.85B -84.73% | 2.03B 92.90% | 1.81B -25.12% | 2.35B 132.36% | 12.13B 653.73% | 1.05B -45.93% | 2.42B 63.45% | 1.01B 12.91% | 1.61B 0.28% | 1.95B -30.59% | 1.48B -26.16% | 893.93M -46.53% | 1.61B -16.09% | 2.81B 126.55% | 2.00B |
EPS - Basic | 0.13 18.18% | -0.02 -104.35% | 0.36 -28.00% | 0.33 -26.67% | 0.11 -81.97% | 0.46 -84.51% | 0.50 51.52% | 0.45 -25.00% | 0.61 134.62% | 2.97 642.50% | 0.33 -45.90% | 0.60 62.16% | 0.26 18.18% | 0.40 0.00% | 0.61 -12.86% | 0.37 -26.00% | 0.22 -47.62% | 0.40 -16.67% | 0.70 125.81% | 0.50 |
EPS - Diluted | 0.13 18.18% | -0.02 -104.44% | 0.36 -28.00% | 0.32 -27.27% | 0.11 -80.70% | 0.45 -84.85% | 0.50 51.52% | 0.44 -26.67% | 0.57 128.00% | 2.97 642.50% | 0.33 -45.90% | 0.60 62.16% | 0.25 13.64% | 0.40 0.00% | 0.61 -12.86% | 0.37 -26.00% | 0.22 -46.34% | 0.40 -16.67% | 0.70 125.81% | 0.50 |
EBIT | 1.14B -8.06% | 3.05B -6.93% | 2.93B 17.77% | 2.85B 22.02% | 1.24B -26.19% | 3.28B 15.75% | 2.49B 8.85% | 2.34B -27.92% | 1.68B 10.81% | 2.83B 1.80% | 2.28B 12.34% | 3.24B 39.97% | 1.51B -29.23% | 2.78B -12.77% | 2.03B 5.56% | 2.31B -27.25% | 2.14B -0.59% | 3.19B 0.23% | 1.92B -23.82% | 3.18B |
EBITDA | 2.19B 8.81% | 4.29B 6.90% | 3.73B 22.36% | 3.55B 13.91% | 2.01B 19.22% | 4.01B 1.37% | 3.05B -0.83% | 3.11B -25.61% | 1.69B -27.98% | 3.96B -1.94% | 3.08B 10.13% | 4.18B 48.78% | 2.34B -2.32% | 4.03B 17.31% | 2.79B 28.76% | 2.81B -18.01% | 2.40B 0.66% | 3.44B -9.83% | 2.17B -38.44% | 3.43B |
Depreciation Depletion & Amortization | 1.05B 35.84% | 1.24B 68.77% | 806.08M 42.52% | 696.24M -10.43% | 773.36M 8147.63% | 732.66M -34.85% | 565.58M -28.70% | 777.28M -17.67% | 9.38M -98.87% | 1.12B -10.24% | 793.23M 4.21% | 944.14M 89.80% | 828.77M 220.23% | 1.25B 400.45% | 761.16M 211.51% | 497.44M 100.40% | 258.80M 12.34% | 250.35M -60.41% | 244.34M -75.50% | 248.22M |
Free Financial AI Agent for Investment
Ask any investment related question and get answer instantly
Is GSK earnings result positive or negative?How should I trade on GSK earnings?GSK FAQs
What is GSK's PE Ratio in 2025/4/4?
GSK's PE ratio in April 4, 2025 is 22.96. This indicates the price investors are willing to pay for $1 of earnings.
What is GSK's PS Ratio in 2025/4/4?
GSK's PS ratio in April 4, 2025 is 1.84. This indicates how much investors are willing to pay for each dollar of the company's sales.
What is GSK's Dividend Yield in 2024/Q4?
GSK's Dividend Yield in 2024/Q4 is 4.52%. This represents the return on investment from dividends relative to the stock price.
What is GSK's Gross Margin in 2024/Q4?
GSK's Gross Margin in 2024/Q4 is 68.93. Gross Margin is typically calculated as (Revenue - Cost of Goods Sold) / Revenue and is a key indicator of a company's financial health and efficiency in managing production costs.
Free Financial AI Agent for Investment
Ask any investment related question and get answer instantly
Is GSK earnings result positive or negative?How should I trade on GSK earnings?